* If you want to update the article please login/register
PFS risk analyses were performed using Kaplanu2010Meier charts and cox proportional hazards models using diagnosis alone or as time-u2010 dependent predictors to determine the effect of veliparib in combination with carboplatin/paclitaxel and monotherapy as time-u2010 dependent predictors. A modest, non-scientific benefit of adding veliparib to carboplatin/paclitaxel is shown by a significantly larger benefit of adding veliparib to the carboplatin/paclitaxel. When veliparib was administered in combination with carboplatin/paclitaxel or monotherapy, a flat correlation was revealed as an additional time-varying predictor in the cox proportional hazards model. If carboplatin/paclitaxel were discontinued before disease progression in this patient population, these results support the dose regimen of veliparib in combination with carboplatin/paclitaxel and continuation of veliparib as monotherapy.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions